Correction: DanCann Pharma A/S invites to an investor presentation and Q&A session in relation to ongoing exercise period of warrants
Correction of earlier press release published today: The previous press release stated that the investor presentation took place on May 4, which was an error. It has now been corrected to May 26.
COPENHAGEN, Denmark, 24 May 2023 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby invites shareholders and warrant holders to a presentation and Q/A session regarding the ongoing warrant exercise period.
In connection with the exercise period of DanCann Pharma’s warrants of series TO 2 the Company invite shareholders and warrant holders to an investor presentation and Q&A that will be held by CEO Jeppe Krog Rasmussen.
The investor presentation and Q&A session will take place on Friday, May 26th, from 10:00 PM to 10.45 PM.
Registration for the presentation/Q&A session can be done at this link (or: https://events.teams.microsoft.com/event/10ab5971-b794-47f4-ac19-cd6701fdf375@02fed67d-4a5d-4ebb-8ff5-b4bb07ecd6f5).
You can already now send in potential questions to DanCann Pharma’s CEO Jeppe Krog Rasmussen, at: jkr@dancann.com.
Due to that Monday the 29th May is a holiday period in Denmark and therefore the stock exchange is closed the last day of trading in the warrants are the 26th of May instead of earlier communicated 29th of May.
Information about warrants of series TO 2
Each warrant of series TO 2 entitles the holder to subscribe for one (1) new share in DanCann Pharma during the exercise period that runs from 16 May until and including 31 May 2023. The subscription price for warrants of series TO 2 has been set at DKK 0.36 per share. At full utilization of warrants of series TO 2, the company will be provided proceeds of approx. DKK 8 million before deduction of transaction related costs.
For warrants not to expire and lose their value, an action from the warrant holder is required. The
holder of warrants of series TO 2 must apply for subscription of new shares, by the exercise of warrants, no later than 5 p.m. CEST 31 May 2023, alternatively sell the warrants no later than 26 May 2023. Some banks might have different dates regarding the last day to exercise.
Upon full exercise of warrants of series TO 2, the number of shares in DanCann Pharma will increase by 21 927 810 shares, to a total of 86 942 449 shares and the share capital will increase by DKK 822 292.875 to DKK 3 260 341.8375. The dilution at full utilization amounts to approx. 25,2 percent of the capital and votes.
Complete terms and conditions for warrants of series TO 2 are available on the company’s website (www.dancann.com). An information brochure containing summary information about DanCann Pharma, and the warrant exercise will be available on the websites of DanCann Pharma.
Important dates
26 May 2023– Last day for trading in warrants
31 May 2023 – The exercise period ends. Some banks might close the exercise period earlier.
2 June 2023 – Planned communication of outcome of the warrant exercise
12 June – Planned conversion of interim shares to common shares
Advisors
Corpura Fondkommission AB, www.corpura.se, acts as Financial Advisor.
Nordic Issuing acts as settlement agent.
For additional information about the warrants, please contact:
Corpura Fondkommission AB
E-mail: info@corpura.se
www.corpura.se
For additional information about the warrants, please contact:
Corpura Fondkommission AB
E-mail: info@corpura.se
www.corpura.se
About DanCann Pharma
DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a licensed production and distribution Company.
The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.
DanCann Pharma is EU-GMP-approved by the Danish Medicines Agency under the Danish Pilot Programme for medical cannabis, and have, among other things, license for manufacturing, export, import and distribution. The DanCann Pharma group also owns the subsidiary CannGros ApS, which is the market leader in Denmark with the import and distribution of the products Bedrocan®, Bedica® and Bediol® to all the Danish pharmacies.
DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm and side listed on OTCQB Venture Market in USA (OTCQB: DCPXF).
For more information, visit: www.dancann.com
For further information, please contact:
Jeppe Krog Rasmussen, CEO
E-mail: jkr@dancann.com
Website: www.dancann.com
Forward-looking-statement:
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.
Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.
Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.